drugset / Trial / NCT00041262

Combination Chemotherapy in Treating Patients With Esophageal Cancer

NCT00041262

Phase 3 Unknown 1300 enrolled Medical Research Council
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating esophageal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who are undergoing surgery for esophageal cancer.

Timeline

Start
2004-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 60 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 80 mg/m2 Intravenous
Subject Epirubicin Small molecule 50 mg/m2 Intravenous
Subject fluorouracil Small molecule 1000 mg/m2 Intravenous

Indications